全身皮质类固醇联合雾化肾上腺素治疗重症毛细支气管炎的实用随机试验
这项实用、多中心、开放标签随机试验纳入18个月以下临床诊断毛细支气管炎并接受正压支持的患儿,比较全身皮质类固醇联合雾化肾上腺素与标准治疗。
要点
- 干预组41例(38%)发生至少1次不良事件,对照组39例(38%)。
- 研究对象为18个月以下临床诊断毛细支气管炎并接受正压支持的患儿。
核心结论
- 在重症毛细支气管炎患儿中,与标准治疗相比,规律使用全身皮质类固醇联合吸入肾上腺素可缩短临床医生管理的正压支持时间。
研究设计与样本
- 共210例患儿接受正压支持,其中皮质类固醇-肾上腺素组107例,对照组103例。
主要发现
- 干预组41例(38%)发生至少1次不良事件,对照组39例(38%)。
关键数值与推荐
- 干预组方案:相当于泼尼松龙13 mg/kg共3天,随后1 mg/kg每日共3天;联合雾化1%肾上腺素0.05 mL/kg用0.9%盐水补至6 ml,经喷射雾化器面罩以12 l/min氧气驱动,每30分钟1次共5次,随后1-4小时1次共3天,之后按需共3天。
- 主要结局为重症监护中临床医生管理的正压支持时间,定义为高流量鼻导管氧疗、鼻咽持续气道正压或机械通气。
临床怎么用
- 对于重症毛细支气管炎接受正压支持的患儿,可考虑全身皮质类固醇联合雾化肾上腺素方案以缩短正压支持时间。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether the combination of systemic corticosteroids and nebulized epinephrine, compared with standard care, reduces the duration of positive pressure support in children with bronchiolitis admitted to intensive care. STUDY DESIGN: We performed a pragmatic, multicenter, open-label, randomized trial between July 2013 and November 2019 in children younger than 18 months old with a clinical diagnosis of bronchiolitis. The intervention group received the equivalent of 13 mg/kg prednisolone over 3 days, then 1 mg/kg daily for 3 days, plus 0.05 mL/kg of nebulized 1% epinephrine made up to 6 ml with 0.9% saline via jet nebulizer and mask using oxygen at 12 l/min every 30 minutes for 5 doses, then 1-4 hourly for 3 days, then as required for 3 days. The primary outcome was clinician-managed duration of positive pressure support in intensive care defined as high-flow nasal-prong oxygen, nasopharyngeal continuous positive airway pressure, or mechanical ventilation. RESULTS: In total, 210 children received positive pressure support. In the corticosteroid-epinephrine group, 107 children received positive pressure support for a geometric mean of 26 (95% CI, 22-32) hours compared with 40 (95% CI 34-47) hours in 103 controls, adjusted ratio 0.66 (95% CI 0.51-0.84), P = .001. In the intervention group, 41 (38%) children experienced at least 1 adverse event, compared with 39 (38%) in the control group. CONCLUSIONS: In children with severe bronchiolitis, the duration of clinician-managed pressure support was reduced by regular treatment with systemic corticosteroids and inhaled epinephrine compared with standard care. CLINICAL TRIAL REGISTRATION: Australian Clinical Trials Research Network: ACTRN12613000316707.
引用
- Gelbart B, McSharry B, Delzoppo C, et al. Pragmatic Randomized Trial of Corticosteroids and Inhaled Epinephrine for Bronchiolitis in Children in Intensive Care. J Pediatr. 2022. PMID: 35093318. doi:10.1016/j.jpeds.2022.01.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。